Back Pain News and Research

Latest Back Pain News and Research

Alexion Pharmaceuticals completes enrollment in Soliris clinical studies for aHUS

Alexion Pharmaceuticals, Inc. today announced that it has completed enrolling patients in all four previously announced prospective, open-label clinical studies investigating Soliris® (eculizumab) as a potential treatment for patients with atypical Hemolytic Uremic Syndrome (aHUS) being conducted in North America and multiple European countries.

21 Apr 2010

Homeopathy – Is it a safer and effective alternative?

Studies have shown that nearly 45% Britons rely on Homeopathy, a branch of medicine that has been doubted by many and loved by an equal number.

20 Apr 2010

Exercise machine for lumbago

Low back pain (or lumbago) is a common ailment often triggered by something as simple as lifting a suitcase. What is the best way to remedy the situation? An exercise machine designed specifically for back muscles could be the solution according to a new study published in the Journal of the American College of Sports Medicine.

20 Apr 2010

Prostate cancer patients having robotic prostatectomy enjoy significant benefits: Study

A new study of almost 700 patients from The Mount Sinai Medical Center shows that prostate cancer patients who had robotically assisted prostatectomy enjoyed significant benefits over patients who had a traditional open radical prostatectomy, including decreased surgical and recovery time, less blood loss during surgery and significantly shorter hospital stays.

16 Apr 2010

Alexion Pharmaceuticals' Soliris NDA for PNH receives approval in Japan

Alexion Pharmaceuticals, Inc. and Alexion Pharma International Sàrl today announced that Japan's Ministry of Health, Labour and Welfare (MHLW) has approved the Company's New Drug Application (NDA) for the use of Soliris® (eculizumab) as a treatment for patients in Japan with paroxysmal nocturnal hemoglobinuria (PNH).

16 Apr 2010

Trans-urethral prostate hyperthermia treatment offers 100% response rate

According the Dr. Friedrich Douwes, Medical Director of St. George Hospital in Bad Aibling, Germany, president of the German Oncological Society and the author of several hundred scientific articles and books, trans-urethral prostate hyperthermia has a 100% initial response rate.

16 Apr 2010

Patients with RLS using rotigotine achieve sustained improvements

New data presented at the 62nd American Academy of Neurology annual meeting in Toronto, Canada, showed that patients with moderate to severe Restless Legs Syndrome using rotigotine achieved sustained improvements in symptoms over 5 years of treatment.

15 Apr 2010

New findings point to potential dysfunctional learning process in chronic pain patients

New research reveals why a stimulus that healthy human subjects perceive as a reward might be processed quite differently in the brains of humans suffering from chronic pain.

15 Apr 2010

Phase II GAMMAGARD clinical study for Alzheimer's disease: 18-month results announced

Baxter International Inc. and New York-Presbyterian Hospital/Weill Cornell Medical Center today announced results of an 18-month Phase II clinical study of GAMMAGARD LIQUID and GAMMAGARD S/D [Immune Globulin Intravenous (Human)] (marketed as KIOVIG outside of the U.S.) for mild-to-moderate Alzheimer's disease. This marked the first announcement of clinical trial results measuring function and cognition in patients who received uninterrupted GAMMAGARD for a period of 18 months.

From Baxter International Inc. 15 Apr 2010

Study suggests patients with low-back pain may benefit from chiropractic treatment

Low-back pain sufferers can seek relief from any number of health professionals, orthopedists, physical therapists and osteopaths among them.

15 Apr 2010

Clinical trial data on AMPYRA Extended Release Tablets to be presented at AAN Annual meeting

Acorda Therapeutics, Inc. today announced that four new analyses of clinical trial data on AMPYRA™ (dalfampridine) Extended Release Tablets 10 mg are being presented at the 62nd American Academy of Neurology Annual meeting.

13 Apr 2010

Health care experts brand plan for a “Big Australia” as disaster waiting to happen

Increased immigration rates are set to make Australia’s population hit 36 million by the year 2050 according to Federal Government estimates. This would be a huge leap from the present 22,300,000 people that the nation has today. The added population is being seen as a necessity to ensure economical survival for the country.

13 Apr 2010

Survey reveals Gamunex as preferred IGIV therapy among neurologists

Talecris Biotherapeutics, Inc., today announced results of a new survey showing that Gamunex® (Immune Globulin Intravenous [Human], 10% Caprylate/Chromatography Purified) is the preferred immune globulin intravenous (IGIV) among neurologists who indicated a brand preference. In the survey, conducted online by Harris Interactive® on behalf of Talecris, neurologists selected Gamunex over four times more often than all other available liquid IGIV therapies, with a statistically significant margin (p<0.05).

13 Apr 2010

Complex back surgeries skyrocket, raising concerns about cost, complications

NPR: "Too many complex back surgeries are being done and people are suffering as a result, according to a study in the current issue of the Journal of the American Medical Association. The general tendency noted in the study — that many patients and doctors think more medical care is always better — has implications for the new health overhaul law.

8 Apr 2010

King Pharmaceuticals commences Phase IIb clinical trial of ELADUR for chronic low back pain

DURECT Corporation announced today that its licensee, King Pharmaceuticals, has begun a Phase IIb clinical trial to evaluate ELADUR™ (TRANSDUR™-Bupivacaine) for the treatment of chronic low back pain. ELADUR is an investigational transdermal drug patch intended to deliver bupivacaine for up to 3 days from a single application.

7 Apr 2010

Nanoparticle-core polymer holds promise as weight-bearing replacement for traditional graft materials

Orthopedic surgeons are often hamstrung by less-than-ideal grafting material when performing surgeries for complex bone injuries resulting from trauma, aging or cancer. Conventional synthetic bone grafts are typically made of stiff polymers or brittle ceramics, and cannot readily conform to the complex and irregular shapes that often result from injury; in addition, they often require metallic fixation devices that require open surgeries to insert and remove.

6 Apr 2010

Sunshine vitamin cures common health problems

What do obesity, heart disease, depression, diabetes, and fibromyalgia have in common? The answer is vitamin D deficiency. More than 200 million Americans lack this essential vitamin and as a result suffer from a host of daily annoyances, chronic conditions, and even life-threatening illnesses.

2 Apr 2010

Lifetime Television to feature XenaCare Holdings' OTC pain reliever Cobroxin

XenaCare Holdings, Inc., a company specializing in the marketing and retail distribution of consumer healthcare products, has announced today that its over-the-counter (OTC) pain reliever, Cobroxin, will be featured on a segment of The Balancing Act, a morning show that airs on the top-rated women's cable television network, Lifetime Television.

1 Apr 2010

Study comparing Plasma Disc Decompression with epidural steroid injections for lumbar disc herniation

ArthroCare Corp., a leader in developing state-of-the-art, minimally invasive surgical products, announced today the publication of an important clinical trial demonstrating that patients treated with ArthroCare's Plasma Disc Decompression (PDD) products experienced reduced pain and better quality of life scores compared to patients treated with the current standard care, epidural steroid injections.

31 Mar 2010

Nutra Pharma's Cobroxin pain reliever now available at CVS stores

Nutra Pharma Corp., a biotechnology company that is developing treatments for Adrenomyeloneuropathy, HIV and Multiple Sclerosis, has announced today that its over-the-counter pain reliever, Cobroxin, is now available for purchase in CVS.

31 Mar 2010

Back Pain News and Research

Latest Back Pain News and Research

Alexion Pharmaceuticals completes enrollment in Soliris clinical studies for aHUS

Homeopathy – Is it a safer and effective alternative?

Exercise machine for lumbago

Prostate cancer patients having robotic prostatectomy enjoy significant benefits: Study

Alexion Pharmaceuticals' Soliris NDA for PNH receives approval in Japan

Trans-urethral prostate hyperthermia treatment offers 100% response rate

Patients with RLS using rotigotine achieve sustained improvements

New findings point to potential dysfunctional learning process in chronic pain patients

Phase II GAMMAGARD clinical study for Alzheimer's disease: 18-month results announced

Study suggests patients with low-back pain may benefit from chiropractic treatment

Clinical trial data on AMPYRA Extended Release Tablets to be presented at AAN Annual meeting

Health care experts brand plan for a “Big Australia” as disaster waiting to happen

Survey reveals Gamunex as preferred IGIV therapy among neurologists

Complex back surgeries skyrocket, raising concerns about cost, complications

King Pharmaceuticals commences Phase IIb clinical trial of ELADUR for chronic low back pain

Nanoparticle-core polymer holds promise as weight-bearing replacement for traditional graft materials

Sunshine vitamin cures common health problems

Lifetime Television to feature XenaCare Holdings' OTC pain reliever Cobroxin

Study comparing Plasma Disc Decompression with epidural steroid injections for lumbar disc herniation

Nutra Pharma's Cobroxin pain reliever now available at CVS stores

Precision in every drop: Inside Hamilton’s syringe technology

Exploring the Future of Neuroscience Drug Discovery

Genomic conservation in Thailand's mangroves

Back Pain News and Research

Latest Back Pain News and Research

Precision in every drop: Inside Hamilton’s syringe technology

Exploring the Future of Neuroscience Drug Discovery

Genomic conservation in Thailand's mangroves

Newsletters you may be interested in